文献速递脑血管病

阿哌沙班、达比加群与利伐沙班对比华法林在非瓣膜性房颤合并卒中或TIA患者中的有效性与安全性

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
PubMed 文献 · Stroke · 2017-06-27

基于MarketScan索赔数据(2012年1月至2015年6月)的回顾性队列研究,纳入非瓣膜性房颤且有既往缺血性卒中/TIA病史的成人,采用倾向评分1:1匹配分别比较阿哌沙班(n=2514)、达比加群(n=1962)、利伐沙班(n=5208)与华法林。结果显示利伐沙班降低缺血性卒中或颅内出血复合终点(HR 0.45,95%CI 0.29-0.72),阿哌沙班和达比加群无显著差异;所有NOAC大出血风险与华法林无显著差异。

要点

  • 利伐沙班较华法林显著降低缺血性卒中或颅内出血复合终点风险。
  • 阿哌沙班和达比加群对缺血性卒中或颅内出血复合终点无显著影响。
  • 三种NOAC大出血风险与华法林相比均无显著差异。

核心结论

  • 在非瓣膜性房颤合并既往卒中/TIA患者中,三种NOAC在缺血性卒中、颅内出血或大出血风险方面不劣于华法林。

研究设计与样本

  • 回顾性队列研究,使用MarketScan索赔数据(2012年1月至2015年6月),纳入新启动口服抗凝的非瓣膜性房颤成人患者,要求≥2个诊断代码、既往缺血性卒中/TIA病史及≥180天连续医疗和处方福利。
  • 采用1:1倾向评分匹配分别比较阿哌沙班 vs 华法林(n=2514)、达比加群 vs 华法林(n=1962)、利伐沙班 vs 华法林(n=5208)。
  • 随访至复合终点(缺血性卒中或颅内出血或大出血)、换药/停药、保险脱保或随访结束,匹配队列平均随访0.5至0.6年。

主要发现

  • 阿哌沙班 vs 华法林:缺血性卒中或颅内出血复合终点HR 0.70(95%CI 0.33-1.48),大出血HR 0.79(95%CI 0.38-1.64)。
  • 达比加群 vs 华法林:缺血性卒中或颅内出血复合终点HR 0.53(95%CI 0.26-1.07),大出血HR 0.58(95%CI 0.26-1.27)。
  • 利伐沙班 vs 华法林:缺血性卒中或颅内出血复合终点HR 0.45(95%CI 0.29-0.72),大出血HR 1.07(95%CI 0.71-1.61)。
  • 三种NOAC分析中颅内出血发生率为0.16至0.61事件/100人年,任何NOAC与华法林相比均无显著差异。

临床怎么用

  • 对于非瓣膜性房颤合并既往卒中/TIA患者,可考虑使用NOAC作为华法林的替代选择。
  • 利伐沙班可能降低缺血性卒中或颅内出血复合终点风险,但需结合个体情况评估。

局限性

  • 回顾性索赔数据分析可能存在残余混杂和错分偏倚。
  • 平均随访时间较短(0.5至0.6年),长期结局未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Limited real-world data exist comparing each non-vitamin K antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial fibrillation who have had a previous ischemic stroke or transient ischemic attack. METHODS: Using MarketScan claims from January 2012 to June 2015, we identified adults newly initiated on oral anticoagulation, with ≥2 diagnosis codes for nonvalvular atrial fibrillation, a history of previous ischemic stroke/transient ischemic attack, and ≥180 days of continuous medical and prescription benefits before anticoagulation initiation. Three analyses were performed comparing 1:1 propensity score-matched cohorts of apixaban versus warfarin (n=2514), dabigatran versus warfarin (n=1962), and rivaroxaban versus warfarin (n=5208). Patients were followed until occurrence of a combined end point of ischemic stroke and intracranial hemorrhage (ICH) or major bleed, switch/discontinuation of index oral anticoagulation, insurance disenrollment, or end of follow-up. Mean follow-up was 0.5 to 0.6 years for all matched cohorts. RESULTS: Using Cox regression, neither apixaban nor dabigatran reduced the combined primary end point of ischemic stroke or ICH (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.33-1.48 and HR, 0.53; 95% CI, 0.26-1.07) and had nonsignificant effect on hazards of major bleeding (HR, 0.79; 95% CI, 0.38-1.64 and HR, 0.58; 95% CI, 0.26-1.27) versus warfarin. Rivaroxaban reduced the combined end point of ischemic stroke or ICH (HR, 0.45; 95% CI, 0.29-0.72) without an effect on major bleeding (HR, 1.07; 95% CI, 0.71-1.61). ICH occurred at rates of 0.16 to 0.61 events per 100 person-years in the 3 NOAC analyses, with no significant difference for any NOAC versus warfarin. CONCLUSIONS: Results from our study of the 3 NOACs versus warfarin in nonvalvular atrial fibrillation patients with a previous history of stroke/transient ischemic attack are relatively consistent with their respective phase III trials and previous stroke/transient ischemic attack subgroup analyses. All NOACs seemed no worse than warfarin in respect to ischemic stroke, ICH, or major bleeding risk.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Coleman CI, Peacock WF, Bunz TJ, et al. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017. PMID: 28655814. doi:10.1161/STROKEAHA.117.017474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。